miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction

• Published in: British journal of pharmacology 2025-01, Vol.182 (2), p.417-431
• Main Authors: Collado, Aida, Jiao, Tong, Kontidou, Eftychia, Carvalho, Lucas Rannier Ribeiro Antonino, Chernogubova, Ekaterina, Yang, Jiangning, Zaccagnini, Germana, Zhao, Allan, Tengbom, John, Zheng, Xiaowei, Rethi, Bence, Alvarsson, Michael, Catrina, Sergiu‐Bogdan, Mahdi, Ali, Carlström, Mattias, Martelli, Fabio, Pernow, John, Zhou, Zhichao
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Aorta - metabolism; Cell culture; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - metabolism; Endothelial cells; Endothelial Cells - metabolism; endothelial dysfunction; Endothelium; Endothelium, Vascular - metabolism; Glucose; high glucose; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; MicroRNAs - genetics; MicroRNAs - metabolism; miRNA; miR‐210; Nitric oxide; Oxidative Stress; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - genetics; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - metabolism; Protein-tyrosine-phosphatase; Therapeutic targets; Transcriptomes; Transgenic animals; Transgenic mice; type 2 diabetes
• ISSN: 0007-1188; 1476-5381; 1476-5381
• DOI: 10.1111/bph.17329

Background and Purpose MicroRNA (miR)‐210 function in endothelial cells and its role in diabetes‐associated endothelial dysfunction are not fully understood. We aimed to characterize the miR‐210 function in endothelial cells and study its therapeutic potential in diabetes. Experimental Approach Two different diabetic mouse models (db/db and Western diet‐induced), miR‐210 knockout and transgenic mice, isolated vessels and human endothelial cells were used. Key Results miR‐210 levels were lower in aortas isolated from db/db than in control mice. Endothelium‐dependent relaxation (EDR) was impaired in aortas from miR‐210 knockout mice, and this was restored by inhibiting miR‐210 downstream protein tyrosine phosphatase 1B (PTP1B), mitochondrial glycerol‐3‐phosphate dehydrogenase 2 (GPD2), and mitochondrial oxidative stress. Inhibition of these pathways also improved EDR in both diabetic mouse models. High glucose reduced miR‐210 levels in endothelial cells and impaired EDR in mouse aortas, effects that were reversed by overexpressing miR‐210. However, plasma miR‐210 levels were not affected in individuals with type 2 diabetes (T2D) following improved glycaemic status. Of note, genetic overexpression using miR‐210 transgenic mice and pharmacological overexpression using miR‐210 mimic in vivo ameliorated endothelial dysfunction in both diabetic mouse models by decreasing PTP1B, GPD2 and oxidative stress. Genetic overexpression of miR‐210 altered the aortic transcriptome, decreasing genes in pathways involved in oxidative stress. miR‐210 mimic restored decreased nitric oxide production by high glucose in endothelial cells. Conclusion and Implications This study unravels the mechanisms by which down‐regulated miR‐210 by high glucose induces endothelial dysfunction in T2D and demonstrates that miR‐210 serves as a novel therapeutic target. LINKED ARTICLES This article is part of a themed issue Non‐coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc